secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001689375-25-000022
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports Q1 net loss of $17.3M, gets EU clearance for DMD exon 44 trial, cuts workforce 20%
--------------------------------------------------------------------------------

- Net loss of $17.3M in Q1 2025 vs net income $23.5M Q1 2024; collaboration revenue fell to $20.6M from $59.1M.
- EU authorization received for Phase 1/2 MAD study (ELEVATE-44-201) of ENTR-601-44; Q2 2025 initiation on track.
- Additional DMD programs: ENTR-601-45 study initiation Q3 2025; ENTR-601-50 regulatory submission H2 2025.
- Workforce reduced ~20% to focus on DMD clinical pipeline and key preclinical programs; cash runway into Q2 2027 ($382.5M).
- Vertex-partnered VX-670 for DM1 continues enrollment in MAD portion of Phase 1/2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/0001689375-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/trda-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer